Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients?

Oncology

Volumn 78, Issue 3-4, 2010, Pages 189-195

  Varga, Dominic ^a,c   Wischnewsky, Manfred ^b   Atassi, Ziad ^a   Wolters, Regine ^b   Geyer, Verena ^a   Strunz, Kathrin ^a   Kreienberg, Rolf ^a   Woeckel, Achim ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c NONE   (Germany)

Author keywords

Early onset breast cancer; Guideline adherence; Outcome; Risk assessment

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77951040370     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313698     Document Type: Article

References (13)

1. SEER Cancer Statistics Review, 1975-2005. Bethesda, National Cancer Institute, 2008.
2. Maggard MA, O Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY: Do young breast cancer patients have worse outcomes? J Surg Res 2003; 113: 109-113.
3. Kim SH, Simkovich-Heerdt A, Tran KN, Maclean B, Borgen PI: Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy. J Am Coll Surg 1998; 187: 1-8.
4. Pritchard KI: Adjuvant therapy of the very young woman. Breast 2007; 16(suppl 2):S136-S146.
5. Figueiredo JC, Ennis M, Knight JA, Mc-Laughlin JR, Hood N, et al: Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat 2007; 105: 69-80.
6. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, et al: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007; 143: 109-118.
7. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-2310.
8. Leconte I, Feger C, Galant C, Berlière M, Berg BV, et al: Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density. AJR Am J Roent -genol 2003; 180: 1675-1679.
9. Kreienberg R, for the German Cancer Society: Interdisziplinäre S 3-Leitlinie für die Diagnostik und Therapie des Mammakarzinoms der Frau. Munich, Zuckerschwendt Verlag, 2004.
10. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, et al: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer -comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009; 20: 258-264.
11. Aryandono T, Harijadi, Soeripto: Breast cancer in young women: prognostic factors and clinicopathological features. Asian Pac J Cancer Prev 2006; 7: 451-454.
12. Chung M, Chang HR, Bland KI, Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996; 77: 97-103. (Pubitemid 26002742)
13. Hadji P: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2009, E-pub ahead of print.